Matches in SemOpenAlex for { <https://semopenalex.org/work/W4312047539> ?p ?o ?g. }
- W4312047539 endingPage "17" @default.
- W4312047539 startingPage "9" @default.
- W4312047539 abstract "Lung cancer is the top cause of cancer-related fatalities in both men and women around the world, and the second most commonly diagnosed cancer in both men and women. For many patients, traditional chemotherapy (CT) fails to give long-term benefit. Moreover, newer medicines targeting activating mutations in EGFR or ALK have shown increased response rates over CT in the minority of patients with these mutations; however, the majority of patients do not have actionable mutations and will not benefit from targeted therapies. In addition, several combinations of chemotherapeutic medicines with the angiogenesis inhibitor bevacizumab have provided only minor additional benefits. However, immunotherapy using checkpoint inhibitors has shown to have a lot of potential in the treatment of advanced non-SCLC (NSCLC) in recent trials. These new medications encourage the host immune system to recognize tumor cells as foreign invaders and halting their growth. They help alleviate immune system suppression, which allows tumor development to be tolerated. In checkpoint immunotherapy, humanized monoclonal antibodies targeting checkpoint signals such as programmed cell death receptor (PD-1) and programmed cell death ligand are employed (PD-L1). The immune system can be triggered to fight the tumor by inhibiting these receptors and signals. Immunotherapy for advanced lung cancer has created a new paradigm of therapeutic options, with increased survival and response rates and a less severe but distinct side profile when compared to CT. The PD-1 inhibitors nivolumab and pembrolizumab, as well as the PD-L1 inhibitor atezolizumab, have been approved by regulatory authorities for the treatment of advanced NSCLC. Hence, the current review article focuses on the role of immunotherapy, newer agents used for checkpoint inhibitors in lung cancer, their epidemiology, risk factors, side-effect profiles, therapeutic indications, and their mechanism of action for the successful treatment of lung cancer." @default.
- W4312047539 created "2023-01-04" @default.
- W4312047539 creator A5003383462 @default.
- W4312047539 creator A5032075404 @default.
- W4312047539 creator A5035969121 @default.
- W4312047539 creator A5062638702 @default.
- W4312047539 creator A5075477236 @default.
- W4312047539 creator A5091253129 @default.
- W4312047539 date "2022-12-07" @default.
- W4312047539 modified "2023-09-30" @default.
- W4312047539 title "IMMUNOTHERAPY AS NOVEL TREATMENT OF LUNG CANCER: A SYSTEMATIC REVIEW" @default.
- W4312047539 cites W1576436685 @default.
- W4312047539 cites W165232771 @default.
- W4312047539 cites W1973489772 @default.
- W4312047539 cites W1978335582 @default.
- W4312047539 cites W2005369618 @default.
- W4312047539 cites W2007328352 @default.
- W4312047539 cites W2008134508 @default.
- W4312047539 cites W2010263122 @default.
- W4312047539 cites W2024492396 @default.
- W4312047539 cites W2026805792 @default.
- W4312047539 cites W2035698893 @default.
- W4312047539 cites W2056187710 @default.
- W4312047539 cites W2060464099 @default.
- W4312047539 cites W2062126586 @default.
- W4312047539 cites W2065477010 @default.
- W4312047539 cites W2069157431 @default.
- W4312047539 cites W2069813628 @default.
- W4312047539 cites W2075997187 @default.
- W4312047539 cites W2091262320 @default.
- W4312047539 cites W2102634879 @default.
- W4312047539 cites W2110530327 @default.
- W4312047539 cites W2114296164 @default.
- W4312047539 cites W2114731011 @default.
- W4312047539 cites W2116839451 @default.
- W4312047539 cites W2124382899 @default.
- W4312047539 cites W2125334994 @default.
- W4312047539 cites W2125579284 @default.
- W4312047539 cites W2126423964 @default.
- W4312047539 cites W2148080782 @default.
- W4312047539 cites W2154459685 @default.
- W4312047539 cites W2156331665 @default.
- W4312047539 cites W2158424267 @default.
- W4312047539 cites W2167702905 @default.
- W4312047539 cites W2213802610 @default.
- W4312047539 cites W2318271526 @default.
- W4312047539 cites W2342642001 @default.
- W4312047539 cites W2411172148 @default.
- W4312047539 cites W2411711891 @default.
- W4312047539 cites W2416907124 @default.
- W4312047539 cites W2465405903 @default.
- W4312047539 cites W2525493424 @default.
- W4312047539 cites W2531599368 @default.
- W4312047539 cites W2544185683 @default.
- W4312047539 cites W2565918574 @default.
- W4312047539 cites W2596766428 @default.
- W4312047539 cites W2604488177 @default.
- W4312047539 cites W2607087154 @default.
- W4312047539 cites W2724698376 @default.
- W4312047539 cites W2789467697 @default.
- W4312047539 cites W2802042719 @default.
- W4312047539 cites W2808137788 @default.
- W4312047539 cites W2810959452 @default.
- W4312047539 cites W2919091706 @default.
- W4312047539 cites W2945538939 @default.
- W4312047539 cites W2951461777 @default.
- W4312047539 cites W2952892955 @default.
- W4312047539 cites W2989957419 @default.
- W4312047539 cites W3004475955 @default.
- W4312047539 cites W3006273887 @default.
- W4312047539 cites W3028523516 @default.
- W4312047539 cites W3029825027 @default.
- W4312047539 cites W3036882088 @default.
- W4312047539 cites W3040411241 @default.
- W4312047539 cites W3057342925 @default.
- W4312047539 cites W3080117085 @default.
- W4312047539 cites W3083344515 @default.
- W4312047539 cites W3084622183 @default.
- W4312047539 cites W3092159910 @default.
- W4312047539 cites W3093899576 @default.
- W4312047539 cites W3104828024 @default.
- W4312047539 cites W3116483718 @default.
- W4312047539 cites W3128646645 @default.
- W4312047539 cites W3134294543 @default.
- W4312047539 cites W3147104901 @default.
- W4312047539 cites W4211039063 @default.
- W4312047539 cites W994417814 @default.
- W4312047539 doi "https://doi.org/10.22159/ajpcr.2022.v15i12.46133" @default.
- W4312047539 hasPublicationYear "2022" @default.
- W4312047539 type Work @default.
- W4312047539 citedByCount "0" @default.
- W4312047539 crossrefType "journal-article" @default.
- W4312047539 hasAuthorship W4312047539A5003383462 @default.
- W4312047539 hasAuthorship W4312047539A5032075404 @default.
- W4312047539 hasAuthorship W4312047539A5035969121 @default.
- W4312047539 hasAuthorship W4312047539A5062638702 @default.
- W4312047539 hasAuthorship W4312047539A5075477236 @default.
- W4312047539 hasAuthorship W4312047539A5091253129 @default.